-transparent.png){kind=logo}
Seventy-nine patients with an histologically proven disseminated breast cancer, never treated before with additive hormonal therapy, entered into a randomized trial between june 1981 and december 1982. In the first group 44 patients were given continually a daily dose of tamoxifen (TAM) of 20 mg/m2. In the 2nd group 35 patients were given a daily dose of TAM of 20 mg/m2 for 15 days and then an oral daily dose of medroxyprogesterone acetate of 350 mg/m2 for the next 15 days. In both groups I and II, the treatment was stopped at the first manifestation of progression of the disease. The hormonal receptor status was determined in 30 patients of the group I and 23 patients of the group II. An objective response to treatment was observed in 48 per cent of the patients of the group I and 60 per cent of the group II. This difference is not significant (X2 = 1,05). However, the mean duration of therapeutic response is significantly higher in the group II (p = 0,01).
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
August 1989,
Journal of surgical oncology,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
November 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
April 1990,
Tumori,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
July 1991,
Annals of oncology : official journal of the European Society for Medical Oncology,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
November 1989,
Gan to kagaku ryoho. Cancer & chemotherapy,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
January 1992,
Breast cancer research and treatment,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
January 1990,
Gynakologische Rundschau,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
January 1985,
Neoplasma,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
January 1985,
Medical oncology and tumor pharmacotherapy,
E Giralt, and
M Jouve, and
T Palangie, and
B Bretaudeau, and
B Asselain, and
H Magdelenat, and
S Merle, and
A Zajdela, and
P Pouillart
August 1982,
Onkologie,
